Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era

Table 1 Baseline characteristics of 3577 patients with cirrhosis treated with interferon-free regimens

Parameter	2015-2016	2017	2018	2019	2020	2021
Number of patients	1199	827	573	438	199	341
Gender, females/males, n (%)	600 (50)/599 (50)	401 (48.5)/426 (51.5)	251 (43.8)/322 (56.2)	164 (37.4)/274 (62.6)	71 (35.7)/128 (64.3)	140 (41.1)/201 (58.9)
Age (yr), mean ± SD; min-max	58.6 ± 11.8; 21-97	59.4 ± 12.0; 22-87	58.2 ± 13.8; 21-89	55.2 ± 13.2; 26-91	54.6 ± 12.1; 28-83	56.6 ± 12.6; 25-86
Females	62.2 ± 10.8; 25-91	62.1 ± 11; 25-85	61.8 ± 14.2; 21-89	60.3 ± 12.8; 30-91	59.4 ± 12.2; 29-83	60.5 ± 12.3; 25-85
Males	55.1 ± 11.8; 21-97	56.8 ± 12.3; 22-87	55.4 ± 12.8; 27-88	52.1 ± 12.5; 26-89	51.9 ± 11.2; 28-80	53.9 ± 12.1; 30-86
Median (Q1, Q3)	60 (52, 67)	60 (52, 67)	59 (48, 68)	56 (45, 63)	55 (45, 63)	57 (47, 65)
Females, median (Q1, Q3)	63 (57, 69)	62 (56, 70)	62 (54, 73)	61 (52.5, 68)	60 (52, 68)	61 (53, 68.5)
Males, median (Q1, Q3)	57 (47, 63)	57 (48, 65)	56 (45, 64)	51 (42, 61)	52 (44, 60)	52 (44, 63)
BMI, mean ± SD; min-max	27.3 ± 4.5; 13.4-49.4	27.5 ± 4.8; 14.2-45.5	27.1 ± 4.7; 21-89	27.7 ± 5.2; 17-52.5	27.9 ± 5.6; 16-57.4	27.5 ± 4.9; 15.6-50
Comorbidities, n (%)
Any comorbidity	921 (76.8)	682 (82.5)	431 (75.2)	303 (69.2)	141 (70.9)	252 (73.9)
Hypertension	582 (48.5)	384 (46.4)	279 (48.7)	179 (40.9)	72 (36.2)	158 (46.3)
Diabetes	263 (21.9)	212 (25.6)	120 (20.9)	76 (17.4)	44 (22.1)	136 (27)
Renal disease	48 (4)	39 (4.7)	20 (3.5)	10 (2.3)	9 (4.5)	12 (3.5)
Autoimmune diseases	29 (2.4)	14 (1.7)	8 (1.4)	9 (2.1)	2 (1)	3 (0.9)
Non-HCC tumors	20 (1.7)	15 (1.8)	12 (2.1)	12 (2.7)	6 (3)	15 (4.4)
Other	628 (52.4)	560 (67.7)	352 (61.4)	208 (47.5)	147 (73.9)	179 (52.5)
Concomitant medications, n (%)	879 (73.3)	635 (76.8)	431 (75.2)	305 (69.6)	138 (69.3)	245 (71.8)
ALT IU/L, mean ± SD	97.3 ± 66.2	96.4 ± 69.9	96 ± 85	107.1 ± 91.7	114.5 ± 103.8	115.9 ± 101.2
Bilirubin mg/dL, mean ± SD	1.2 ± 0.9	1 ± 0.7	1.1 ± 0.9	1.1 ± 0.9	1.1 ± 1.6	1.1 ± 0.9
Albumin g/dL, mean ± SD	5.8 ± 12.8	3.8 ± 0.5	3.8 ± 0.5	3.9 ± 0.5	3.8 ± 0.5	3.9 ± 0.6
Creatinine mg/dL, mean ± SD	1.1 ± 3.8	0.8 ± 0.5	0.9 ± 0.5	0.9 ± 0.7	0.9 ± 0.3	0.9 ± 0.7
Hemoglobin g/dL, mean ± SD	14.1 ± 1.8	14.1 ± 1.8	14 ± 1.8	14.1 ± 1.9	14.2 ± 1.8	13.9 ± 1.9
Platelets, × 1000/μL, mean ± SD	118.7 ± 61.6	136.1 ± 67.9	135 ± 70	136.5 ± 61.9	145.8 ± 87.6	145.6 ± 76.9
HCV RNA × 106 IU/mL, mean ± SD	1.6 ± 4.6	2.5 ± 6.4	2 ± 4.8	3.3 ± 24	1.7 ± 2.6	2 ± 3.2

IFN: Interferon; SD: Standard deviation; BMI: Body mass index; HCC: Hepatocellular carcinoma; ALT: Alanine transaminase; HCV RNA: Ribonucleic acid of hepatitis C virus.